【摘要】 目的探索奥沙利铂过敏的发生率和临床特征。方法收集2008年3月至2012年12月期间曾接受至少1次奥沙利铂治疗的194例患者的临床资料,分析奥沙利铂过敏的临床特征。结果 194例患者中,21例(10.8%)发生过敏反应,其中3~4度过敏发生率为4.6%。过敏最常发生于第7~8个周期,发生率为7.3%。延迟性发热是最常见的过敏症状;以呼吸和循环系统症状为主要过敏表现者,症状发生最快、程度最严重。结论中国患者奥沙利铂过敏发生率与西方人群或其他亚洲人群类似。第7~8个周期过敏发生率最高,严重过敏多发生在输注开始前10 min,提醒临床医生在此期间密切关注。更多还原

【Abstract】 Objective To explore the incidence and clinical characteristics of oxaliplatin( LOHP)-induced hypersensitivity reactions( HRs) in Chinese patients. Methods Clinical information of all patients treated with L-OHP at least once between March 2008 and December 2012 was collected. Detail data from patients who experienced HRs were analyzed. Results Among 194 patients receiving L-OHP-based chemotherapy,21( 10. 8%) experienced HRs. Grade 3 /4 events occurred in 4. 6%. HRs occurred most frequently in cycle 7-8th( incidence 7. 3%). The most common symptom of HRs was delayed pyrexia. The fastest and severest HRs were observed in those manifesting mainly with respiratory or cardiac symptoms. Conclusions The reaearch data shows the incidence of HRs to L-OHP in Chinese patients is similar to that in western population and other eastern Asian populations. Precautions are recommended for first10 minutes since onset of infusion and cycle 7-8th,given the most serious events and the peak of incidence observed during this period.更多还原